G. Fraser and R. Meyer, Biomarkers and the design of clinical trials in cancer, Biomarkers in Medicine, vol.94, issue.3, pp.387-97, 2007.
DOI : 10.1093/jnci/93.14.1054

D. Spinella, Biomarkers in clinical drug development: realizing the promise, Biomarkers in Medicine, vol.3, issue.6, pp.667-69, 2009.
DOI : 10.2217/bmm.09.61

D. Gruttola, V. Clax, P. , D. Mets, and D. , Considerations in the Evaluation of Surrogate Endpoints in Clinical Trials, Controlled Clinical Trials, vol.22, issue.5, pp.485-502, 2001.
DOI : 10.1016/S0197-2456(01)00153-2

D. Food and . Administration, Table of Pharmacogenomic Biomarkers in Drug Labels [en ligne Disponible sur, 2011.

B. Spear, M. Heath-chiozzi, and J. Huff, Clinical application of pharmacogenetics, Trends in Molecular Medicine, vol.7, issue.5, pp.201-205, 2001.
DOI : 10.1016/S1471-4914(01)01986-4

R. Wolf and S. , Imaging biomarkers as surrogate endpoints for drug developement, European Journal of Nuclear Medicine and Molecular Imaging, vol.33, issue.16, pp.6-10, 2006.

L. Comité-biotech and . Bionest-partner, Le biomarqueur comme outil de diagnostic compagnon de produits thérapeutiques, Impacts sur la R&D et sur les modèles économiques des industriels de la santé

E. Marrer, Promises of Biomarkers in Drug Development ? A Reality Check, Chemical Biology & Drug Design, vol.11, issue.6, pp.381-94, 2007.
DOI : 10.1007/BF03256453

W. Carney, On target? The challenge of integrating biomarker research in drug development, Biomarkers in Medicine, vol.1, issue.1, pp.17-21, 2007.
DOI : 10.2217/17520363.1.1.17

V. Shankaran, Conference presentation at the Gastrointestinal Cancers Symposium, 2009.

A. European-medicines, Vectibix® Summary of Product Characteristics, Disponible sur, 2010.

A. European-medicines, Erbitux® Summary of Product Characteristics [en ligne] Disponible sur: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000558/human_ med_000769.jsp&murl=menus/medicines/medicines, pp.0-01, 2010.

D. Food and . Administration, Vectibix® Product Information [en ligne] Disponible sur: http://www.accessdata.fda.gov, 2009.

D. Food and . Administration, Erbitux® Product Information [en ligne] Disponible sur: http://www.accessdata.fda.gov, 2009.

L. Mangravite, C. Thorn, and R. Krauss, Clinical implications of pharmacogenomics of statin treatment, The Pharmacogenomics Journal, vol.165, issue.4 Suppl, pp.360-74, 2006.
DOI : 10.1016/S0021-9150(02)00196-X

M. Rieder, A. Reiner, and B. Gage, Haplotypes on Transcriptional Regulation and Warfarin Dose, New England Journal of Medicine, vol.352, issue.22, pp.2285-93, 2005.
DOI : 10.1056/NEJMoa044503

S. Terra, K. Hamilton, and D. Pauly, ??1-Adrenergic receptor polymorphisms and left ventricular remodeling changes in response to ??-blocker therapy, Pharmacogenetics and Genomics, vol.15, issue.4, pp.227-261, 2005.
DOI : 10.1097/01213011-200504000-00006

A. Margaret and S. Francis, The Path to Personalized Medicine, N Engl J Med, vol.363, issue.4, pp.434-442, 2010.

J. Shannon, THE RENAL EXCRETION OF CREATININE IN MAN, Journal of Clinical Investigation, vol.14, issue.4, pp.403-413, 1935.
DOI : 10.1172/JCI100691

A. Sundal, A Creatinin Tolerance Test for Renal Function, Acta Paediatrica, vol.17, issue.6, pp.535-544, 1953.
DOI : 10.1042/bj0200447

R. Goldman, Creatinine Excretion in Renal Failure., Experimental Biology and Medicine, vol.85, issue.3, pp.446-454, 1954.
DOI : 10.3181/00379727-85-20912

D. Cockcroft and M. Gault, Prediction of Creatinine Clearance from Serum Creatinine, Nephron, vol.16, issue.1, pp.31-41, 1976.
DOI : 10.1159/000180580

W. Johnson, W. Hagge, R. Wagoner, R. Dinapoli, and J. Rosevear, Effects of urea loading in patients with far-advanced renal failure, Mayo Clin Proc, vol.47, issue.1, pp.21-30, 1972.

W. Knaus, E. Draper, and D. Wagner, Prognosis in Acute Organ-System Failure, Annals of Surgery, vol.202, issue.6, pp.685-93, 1985.
DOI : 10.1097/00000658-198512000-00004

M. Froissard and R. J. , How to improve estimation of renal function in the elderly, Rev Prat, vol.55, issue.20, pp.2223-2232, 2005.

O. Shemesh, H. Golbetz, and J. Kriss, Limitations of creatinine as a filtration marker in glomerulopathic patients, Kidney International, vol.28, issue.5, pp.830-838, 1985.
DOI : 10.1038/ki.1985.205

U. S. Food and D. Administration, Qualification process for drug development tools [en ligne]. 2010 Disponible sur: http://www.fda.gov/downloads, 2011.

A. European-medicines, Qualification of novel technologies for drug development : guidance to applicants, Disponible sur, 0200.

U. S. Food and D. Administration, Guidance for industry: Pharmacogenomic data submission [en ligne]. Mars Disponible sur: http://www.fda.gov, 2005.

E. European-medicines-agency and U. S. Commission, Food and Drug Administration General principles Processing Joint FDA EMEA Voluntary Genomic Data Submissions (VGDSs) within the framework of the confidentiality arrangement, Disponible sur, 2009.

F. Dieterle, F. Sistare, and F. Goodsaid, Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium, Nature Biotechnology, vol.28, issue.5, pp.455-62, 2010.
DOI : 10.1038/nbt0510-436

F. Goodsaid, F. Frueh, and W. Mattes, The Predictive Safety Testing Consortium: A synthesis of the goals, challenges and accomplishments of the Critical Path, Drug Discovery Today: Technologies, vol.4, issue.2, pp.47-50, 2007.
DOI : 10.1016/j.ddtec.2007.10.010

A. European-medicines, Final conclusions on the pilot joint EMEA/FDA VXDS experience on qualification of nephrotoxicity biomarkers, Disponible sur, 0200.

A. European-medicines, Reflection paper on co-development of pharmacogenomic biomarkers and assays in the context of drug development. Draft. [en ligne, 2010.

J. Cummings, T. Ward, and A. Greystoke, Biomarker method validation in anticancer drug development, British Journal of Pharmacology, vol.26, issue.Suppl 1, pp.646-56, 2008.
DOI : 10.1155/2002/929274

J. Cummings, T. Ward, and C. Dive, Fit-for-purpose biomarker method validation in anticancer drug development, Drug Discovery Today, vol.15, issue.19-20, pp.19-20, 2010.
DOI : 10.1016/j.drudis.2010.07.006

B. Legras, Eléments de statistiques à l'usage des étudiants en Médecine et en Biologie, 1998.

U. S. Food and D. Administration, Drug-diagnostic co-development concept paper [en ligne], Disponible via, 2005.

M. Jost, Surrogate end points: how well do they represent patient-relevant end points?, Biomarkers in Medicine, vol.36, issue.3, pp.437-51, 2007.
DOI : 10.1016/0735-1097(94)90408-1

B. Berns, P. Démolis, and M. Scheulen, How can biomarkers become surrogate endpoints? EJC Supplements, pp.37-40, 2007.
DOI : 10.1016/j.ejcsup.2007.09.003

URL : https://doi.org/10.1016/j.ejcsup.2007.09.003

R. Temple, Complexities in drug trials: enrichment, biomarkers and surrogates, Biomarkers in Medicine, vol.2, issue.2, pp.109-121, 2008.
DOI : 10.1002/pds.1211

W. Richter, Imaging biomarkers as surrogate endpoints for drug development, European Journal of Nuclear Medicine and Molecular Imaging, vol.41, issue.S1, pp.6-10, 2006.
DOI : 10.1007/s00259-006-0129-z

R. Duivenvoorden, E. De-groot, and E. Stroes, Surrogate markers in clinical trials???Challenges and opportunities, Atherosclerosis, vol.206, issue.1, pp.8-16, 2009.
DOI : 10.1016/j.atherosclerosis.2008.12.009

T. Fleming and D. Demets, Surrogate end points in clinical trials: are we being misled? Ann Intern Med, pp.605-618, 1996.
DOI : 10.7326/0003-4819-125-7-199610010-00011

D. Gruttola, V. Clax, P. Demets, and D. , Considerations in the Evaluation of Surrogate Endpoints in Clinical Trials, Controlled Clinical Trials, vol.22, issue.5, pp.485-502, 2001.
DOI : 10.1016/S0197-2456(01)00153-2

A. European-medicines, Disponible via, Avandia European Public Assessment Report, 2004.

B. Vastag, New clinical trials policy at FDA, Nature Biotechnology, vol.24, issue.9, p.1043, 2006.
DOI : 10.1038/nbt0906-1043

E. /. Efpia and . Workshop, Adaptive Design in Confirmatory Trials, Mars 2010 Disponible via, 2010.

U. S. Food and D. Administration, Adaptive Design Clinical Trials for Drugs and Biologics. Draft guidance [en ligne]. Février 2010 Disponible via : http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances, 2011.

R. Mahajan and K. Gupta, Adaptive design clinical trials: Methodology, challenges and prospect, Indian Journal of Pharmacology, vol.42, issue.4, pp.201-208, 2010.
DOI : 10.4103/0253-7613.68417

URL : https://doi.org/10.4103/0253-7613.68417

B. Freidlin and E. Korn, Biomarker-adaptive clinical trial designs, Pharmacogenomics, vol.90, issue.12, pp.1679-82, 2010.
DOI : 10.1158/1078-0432.CCR-09-1357

S. Wang, Utility of Adaptive Strategy and Adaptive Design for Biomarker-facilitated Patient Selection in Pharmacogenomic or Pharmacogenetic Clinical Development Program, Journal of the Formosan Medical Association, vol.107, issue.12, pp.19-27, 2008.
DOI : 10.1016/S0929-6646(09)60005-X

W. Jiang, B. Freidlin, and R. Simon, Biomarker-Adaptive Threshold Design: A Procedure for Evaluating Treatment With Possible Biomarker-Defined Subset Effect, JNCI Journal of the National Cancer Institute, vol.69, issue.10, pp.1036-1079, 2007.
DOI : 10.1056/NEJMoa050736

A. European-medicines, Reflection paper on methodological issues in confirmatory clinical trials planned with an adaptive design [en ligne]. Octobre, Disponible via, 2007.

A. Barker, C. Sigman, and G. Kelloff, I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy, Clinical Pharmacology & Therapeutics, vol.28, issue.1, pp.97-100, 2009.
DOI : 10.1038/clpt.2009.68

M. Karasarides and A. Chiloeches, B-RAF is a therapeutic target in melanoma, Oncogene, vol.23, issue.37, pp.6292-6300, 2004.
DOI : 10.1038/sj.onc.1207785

K. Flaherty and G. Mcarthur, BRAF, a target in melanoma, Cancer, vol.203, issue.June 1 suppl, pp.4902-4915, 2010.
DOI : 10.1016/S0002-9440(10)62327-9

K. Flaherty, I. Puzanov, and K. Kim, Inhibition of Mutated, Activated BRAF in Metastatic Melanoma, New England Journal of Medicine, vol.363, issue.9, pp.809-828, 2010.
DOI : 10.1056/NEJMoa1002011

C. Carden, D. Sarker, and S. Postel-vinay, Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?, Drug Discovery Today, vol.15, issue.3-4, pp.3-4, 2010.
DOI : 10.1016/j.drudis.2009.11.006

P. Inc, Plexxikon Announces First Patient Dosed in Phase 3 Trial of PLX4032 (RG7204) for Metastatic Melanoma. Press release, Disponible sur, 2010.

C. Gridelli, D. Marinis, F. , D. Maio, and M. , Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence, Lung Cancer, vol.71, issue.3, pp.249-57, 2011.
DOI : 10.1016/j.lungcan.2010.12.008

U. S. Food and D. Administration, FDA alert for Healthcare Professionnals: Geftinib (marketed as Iressa) [en ligne] Disponible sur: http://www.fda.gov

V. Sakanyan and M. Arnaud, Protein arrays and perspectives of medical applications, pp.5-6, 2007.

O. Scaros and R. Fisler, Biomarker technology roundup: from discovery to clinical applications, a broad set of tools is required to translate from the lab to the clinic, BioTechniques, vol.38, issue.S4, pp.30-32, 2005.
DOI : 10.2144/05384SU01

L. Mcshane, S. Hunsberger, and A. Adjei, Effective Incorporation of Biomarkers into Phase II Trials, Clinical Cancer Research, vol.15, issue.6, pp.1898-905, 2009.
DOI : 10.1158/1078-0432.CCR-08-2033

G. A. Kolata, Tale of Two Drugs Hints at Promise for Genetic Testing [en ligne] New York Times Disponible via : http://www.nytimes.com, p.1, 2006.

C. Tate, A. Roberton, and R. Zolty, Quality of Life and Prognosis in Heart Failure: Results of the Beta-Blocker Evaluation of Survival Trial (BEST), Journal of Cardiac Failure, vol.13, issue.9, pp.732-739, 2007.
DOI : 10.1016/j.cardfail.2007.07.001

R. Frank and R. Hargreaves, Clinical biomarkers in drug discovery and development, Nature Reviews Drug Discovery, vol.75, issue.7, pp.566-80, 2003.
DOI : 10.1177/009127001773744260

R. Prentice, Surrogate endpoints in clinical trials: Definition and operational criteria, Statistics in Medicine, vol.248, issue.4, pp.431-471, 1989.
DOI : 10.1002/sim.4780080407

U. S. Food and D. Administration, The critical path initiative: Transforming the way FDA-regulated products are developed, evaluated, manufactured, and used Disponible sur: http://www.fda.gov/downloads, 2009.

E. Selvin, S. Marinopoulos, and G. Berkenblit, Meta-Analysis: Glycosylated Hemoglobin and Cardiovascular Disease in Diabetes Mellitus, Annals of Internal Medicine, vol.141, issue.6, pp.421-452, 2004.
DOI : 10.7326/0003-4819-141-6-200409210-00007

H. Gerstein, M. Miller, and R. Byington, Effects of intensive glucose lowering in type 2 diabetes, N Engl J Med, vol.358, pp.2545-59, 2008.

S. Bamford, E. Dawson, and S. Forbes, The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website, British Journal of Cancer, vol.32, issue.2, pp.355-363, 2004.
DOI : 10.1093/nar/gkh073

M. Brose, P. Volpe, and M. Feldman, BRAF and RAS mutations in human lung cancer and melanoma, Cancer Res, vol.62, pp.6997-7000, 2002.

A. Yazdi, G. Palmedo, and M. Flaig, Mutations of the BRAF Gene in Benign and Malignant Melanocytic Lesions, Journal of Investigative Dermatology, vol.121, issue.5, pp.1160-1162, 2003.
DOI : 10.1046/j.1523-1747.2003.12559.x